447 related articles for article (PubMed ID: 28617319)
21. Apremilast for the treatment of psoriatic arthritis.
Souto A; Gómez-Reino JJ
Expert Rev Clin Immunol; 2015; 11(12):1281-90. PubMed ID: 26503917
[TBL] [Abstract][Full Text] [Related]
22. Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis.
Torres T; Puig L
Am J Clin Dermatol; 2018 Feb; 19(1):23-32. PubMed ID: 28597182
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of PDE4 by apremilast attenuates skin fibrosis through directly suppressing activation of M1 and T cells.
Lu QK; Fan C; Xiang CG; Wu B; Lu HM; Feng CL; Yang XQ; Li H; Tang W
Acta Pharmacol Sin; 2022 Feb; 43(2):376-386. PubMed ID: 33850274
[TBL] [Abstract][Full Text] [Related]
24. The phosphodiesterase 4 inhibitor apremilast inhibits Th1 but promotes Th17 responses induced by 6-sulfo LacNAc (slan) dendritic cells.
Oehrl S; Prakash H; Ebling A; Trenkler N; Wölbing P; Kunze A; Döbel T; Schmitz M; Enk A; Schäkel K
J Dermatol Sci; 2017 Aug; 87(2):110-115. PubMed ID: 28499587
[TBL] [Abstract][Full Text] [Related]
25. Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis.
Abdulrahim H; Thistleton S; Adebajo AO; Shaw T; Edwards C; Wells A
Expert Opin Pharmacother; 2015 May; 16(7):1099-108. PubMed ID: 25864487
[TBL] [Abstract][Full Text] [Related]
26. Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
Keating GM
Drugs; 2017 Mar; 77(4):459-472. PubMed ID: 28213862
[TBL] [Abstract][Full Text] [Related]
27. Apremilast Normalizes Gene Expression of Inflammatory Mediators in Human Keratinocytes and Reduces Antigen-Induced Atopic Dermatitis in Mice.
Schafer PH; Adams M; Horan G; Truzzi F; Marconi A; Pincelli C
Drugs R D; 2019 Dec; 19(4):329-338. PubMed ID: 31598889
[TBL] [Abstract][Full Text] [Related]
28. Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors.
Perez-Aso M; Montesinos MC; Mediero A; Wilder T; Schafer PH; Cronstein B
Arthritis Res Ther; 2015 Sep; 17(1):249. PubMed ID: 26370839
[TBL] [Abstract][Full Text] [Related]
29. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.
Schafer PH; Parton A; Gandhi AK; Capone L; Adams M; Wu L; Bartlett JB; Loveland MA; Gilhar A; Cheung YF; Baillie GS; Houslay MD; Man HW; Muller GW; Stirling DI
Br J Pharmacol; 2010 Feb; 159(4):842-55. PubMed ID: 20050849
[TBL] [Abstract][Full Text] [Related]
30. Safety evaluation of apremilast for the treatment of psoriasis.
Dattola A; Del Duca E; Saraceno R; Gramiccia T; Bianchi L
Expert Opin Drug Saf; 2017 Mar; 16(3):381-385. PubMed ID: 28132578
[TBL] [Abstract][Full Text] [Related]
31. Phosphodiesterase-4 enzyme as a therapeutic target in neurological disorders.
Bhat A; Ray B; Mahalakshmi AM; Tuladhar S; Nandakumar DN; Srinivasan M; Essa MM; Chidambaram SB; Guillemin GJ; Sakharkar MK
Pharmacol Res; 2020 Oct; 160():105078. PubMed ID: 32673703
[TBL] [Abstract][Full Text] [Related]
32. [Progress in PDE4 targeted therapy for inflammatory diseases].
Song SD; Tang HF
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2014 May; 43(3):353-8. PubMed ID: 24998661
[TBL] [Abstract][Full Text] [Related]
33. Phosphodiesterase 4 inhibitors in inflammatory bowel disease: a comprehensive review.
Salari-Sharif P; Abdollahi M
Curr Pharm Des; 2010; 16(33):3661-7. PubMed ID: 21128899
[TBL] [Abstract][Full Text] [Related]
34. Apremilast for the management of moderate to severe plaque psoriasis.
Vangipuram R; Alikhan A
Expert Rev Clin Pharmacol; 2017 Apr; 10(4):349-360. PubMed ID: 28276777
[TBL] [Abstract][Full Text] [Related]
35. Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis.
McCann FE; Palfreeman AC; Andrews M; Perocheau DP; Inglis JJ; Schafer P; Feldmann M; Williams RO; Brennan FM
Arthritis Res Ther; 2010; 12(3):R107. PubMed ID: 20525198
[TBL] [Abstract][Full Text] [Related]
36. Apremilast as a treatment for psoriasis.
Shutty B; West C; Pellerin M; Feldman S
Expert Opin Pharmacother; 2012 Aug; 13(12):1761-70. PubMed ID: 22712800
[TBL] [Abstract][Full Text] [Related]
37. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor: A novel treatment option for nurse practitioners treating patients with psoriatic disease.
Young M; Roebuck HL
J Am Assoc Nurse Pract; 2016 Dec; 28(12):683-695. PubMed ID: 27869356
[TBL] [Abstract][Full Text] [Related]
38. Serum sCD40L levels are increased in patients with psoriatic arthritis and are associated with clinical response to apremilast.
Venerito V; Natuzzi D; Bizzoca R; Lacarpia N; Cacciapaglia F; Lopalco G; Iannone F
Clin Exp Immunol; 2020 Aug; 201(2):200-204. PubMed ID: 32383167
[TBL] [Abstract][Full Text] [Related]
39. Phosphodiesterase 4 inhibitors.
Zebda R; Paller AS
J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S43-S52. PubMed ID: 29248522
[TBL] [Abstract][Full Text] [Related]
40. PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease.
Banner KH; Trevethick MA
Trends Pharmacol Sci; 2004 Aug; 25(8):430-6. PubMed ID: 15276712
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
